Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS
A phase 1/2 trial of 1.0% IP-001 for Injection in colorectal cancer, non-small-cell lung cancer and sarcomas, run by Immunophotonics, Inc., active and no longer recruiting.
Overview
Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS is a phase 1/2 interventional study registered as NCT05688280 by Immunophotonics, Inc., with 42 participants enrolled, started 2022-11-29 and due to reach its primary completion in 2025-02. Interventions recorded: 1.0% IP-001 for Injection.
Similar pages
not linked directly; found by shared links- TrialPhase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.
Shares Colorectal cancer, Non-small-cell lung cancer and the tag pipeline.
- TrialClinical Study of VG161 in the Treatment of Advanced Bone and Soft Tissue Sarcoma
Shares Sarcomas (soft tissue, bone, GIST) and the tag pipeline.
- TrialA Study of RNK08954 in Subjects With Advanced Solid Tumors With KRAS ((Kirsten Rat Sarcoma) G12D Mutation
Shares Sarcomas (soft tissue, bone, GIST) and the tag pipeline.
- TrialFirst-in-Human Study of ADCE-D01 in Soft Tissue Sarcoma
Shares Sarcomas (soft tissue, bone, GIST) and the tag pipeline.
- TrialPhase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors
Shares Colorectal cancer, Non-small-cell lung cancer and the tag pipeline.
- Trial64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer
Shares Sarcomas (soft tissue, bone, GIST), Colorectal cancer and the tag pipeline.
- TrialXian-Lian-Jie-Du Optimization Decoction As an Adjuvant Treatment for Prevention of Recurrence of Colon Cancer
Shares Colorectal cancer and the tag pipeline.
- TrialA Study of CNA3103 (LGR5-targeted, Autologous CAR-T Cells) Administered to Subjects With Metastatic Colorectal Cancer
Shares Colorectal cancer and the tag pipeline.